Tags

Type your tag names separated by a space and hit enter

New developments in serodiagnosis of childhood celiac disease: assay of antibodies against deamidated gliadin.
Ann N Y Acad Sci. 2009 Sep; 1173:28-35.AN

Abstract

Antibodies to deamidated gliadin present a new tool in the diagnosis of celiac disease (CD). In children, the ELISA for the determination of IgG antibodies to (deamidated) gliadin-analogous fusion peptides (GAF3X) has a superior performance compared to the ELISA for the determination of antibodies against native gliadin and is comparable to assays for IgA antibodies against tissue transglutaminase (IgA-anti-tTG). The combined investigation of IgG antibodies to GAF3X (IgG-anti-GAF3X) and IgA-anti-tTG significantly increases the fraction of children definitely identified as either CD or non-CD patients. The new IgG-anti-GAF3X ELISA was also able to detect CD in three cases of IgA deficiency and in two cases of latent CD and was also useful in the diagnosis of children younger than 2 years of age.

Authors+Show Affiliations

Institute of Laboratory Medicine, University Hospital Leipzig, Leipzig, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19758128

Citation

Prause, Christian, et al. "New Developments in Serodiagnosis of Childhood Celiac Disease: Assay of Antibodies Against Deamidated Gliadin." Annals of the New York Academy of Sciences, vol. 1173, 2009, pp. 28-35.
Prause C, Richter T, Koletzko S, et al. New developments in serodiagnosis of childhood celiac disease: assay of antibodies against deamidated gliadin. Ann N Y Acad Sci. 2009;1173:28-35.
Prause, C., Richter, T., Koletzko, S., Uhlig, H. H., Hauer, A. C., Stern, M., Zimmer, K. P., Laass, M. W., Probst, C., Schlumberger, W., & Mothes, T. (2009). New developments in serodiagnosis of childhood celiac disease: assay of antibodies against deamidated gliadin. Annals of the New York Academy of Sciences, 1173, 28-35. https://doi.org/10.1111/j.1749-6632.2009.04638.x
Prause C, et al. New Developments in Serodiagnosis of Childhood Celiac Disease: Assay of Antibodies Against Deamidated Gliadin. Ann N Y Acad Sci. 2009;1173:28-35. PubMed PMID: 19758128.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New developments in serodiagnosis of childhood celiac disease: assay of antibodies against deamidated gliadin. AU - Prause,Christian, AU - Richter,Thomas, AU - Koletzko,Sibylle, AU - Uhlig,H Holm, AU - Hauer,Almuthe C, AU - Stern,Martin, AU - Zimmer,Klaus-Peter, AU - Laass,Martin W, AU - Probst,Christian, AU - Schlumberger,Wolfgang, AU - Mothes,Thomas, PY - 2009/9/18/entrez PY - 2009/9/18/pubmed PY - 2009/10/30/medline SP - 28 EP - 35 JF - Annals of the New York Academy of Sciences JO - Ann N Y Acad Sci VL - 1173 N2 - Antibodies to deamidated gliadin present a new tool in the diagnosis of celiac disease (CD). In children, the ELISA for the determination of IgG antibodies to (deamidated) gliadin-analogous fusion peptides (GAF3X) has a superior performance compared to the ELISA for the determination of antibodies against native gliadin and is comparable to assays for IgA antibodies against tissue transglutaminase (IgA-anti-tTG). The combined investigation of IgG antibodies to GAF3X (IgG-anti-GAF3X) and IgA-anti-tTG significantly increases the fraction of children definitely identified as either CD or non-CD patients. The new IgG-anti-GAF3X ELISA was also able to detect CD in three cases of IgA deficiency and in two cases of latent CD and was also useful in the diagnosis of children younger than 2 years of age. SN - 1749-6632 UR - https://www.unboundmedicine.com/medline/citation/19758128/New_developments_in_serodiagnosis_of_childhood_celiac_disease:_assay_of_antibodies_against_deamidated_gliadin_ L2 - https://doi.org/10.1111/j.1749-6632.2009.04638.x DB - PRIME DP - Unbound Medicine ER -